A Phase 1, Randomized, Double-Blind, Vehicle-Controlled Ascending Doses Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASN008 Topical Gel in Healthy Volunteers and Subjects With Atopic Dermatitis
Latest Information Update: 27 Feb 2023
At a glance
- Drugs ASN-008 (Primary)
- Indications Atopic dermatitis; Pruritus
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Asana BioSciences
- 27 May 2020 Status changed from active, no longer recruiting to completed.
- 10 Mar 2020 Results published in the Asana BioSciences Media Release.
- 01 Nov 2019 Status changed from recruiting to active, no longer recruiting.